Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Care Institute Teams with NextBio to Study Genomic Data

NEW YORK (GenomeWeb News) – NextBio said today that the Cancer Care Institute will use its software under a strategic collaboration to interpret genomic data from cancer patients.

Under the partnership, CCI, which has campuses in San Jose and Morgan Hill, Calif., will apply the NextBio software platform to analyze patients' genomic data and streamline the use of that information in the clinic.

CCI "cares for a very diverse group of patients of many different races and ethnicities, so we often see findings and trends that are not captured in the literature," Morteza Dowlatshahi, CCI's medical director, said in a statement.

Dowlatshahi said the software provides an "easy-to-use way to interpret our patients' genomic data to conduct research studies as well as to identify optimal treatments."

Alpana Verma-Alag, head of clinical development at NextBio, said that using tools for handling large-scale data handling technologies enables the company to "meaningfully interpret the molecular data from a person in a short amount of time, which has phenomenal implications for translational research and patient care."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.